CADTH | pCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

PROVINCIAL FUNDING SUMMARY

Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (previously untreated) (pCODR 10085)

pERC Recommendation: Recommends

For further details, please see pERC Final Recommendation

Notification to Implement Issued by pCODR: November 18, 2016

This information is current as of May 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Oct 1, 2016	Chronic lymphocytic leukemia or small lymphocytic lymphoma with chromosome 17 p deletion and no prior therapy • AST/ALT less than 3 x ULN • A Compassionate Access Program (CAP) approval is required prior to the initiation of treatment
AB	Funded	May 8, 2018	Criteria Updated: For the treatment of patients with previously untreated del(l7p) and /or TP53 mutation chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This high risk group of patients also includes young, fit patients with unmutated IgHV status. Treatment should be for patients with a good performance status and until disease progression or unacceptable toxicity.
SK	Funded	Oct 1, 2017	For patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) for whom Fludarabine-based treatment is considered inappropriate. Notes: -Ibrutinib may be continued until disease progression -Ibrutinib is not funded as a sequential treatment option for patients who have progressed on Idelalisib treatment -Anti-CD20 therapy in combination with chemotherapy is not funded after Ibrutinib failure.
MB	Funded	Oct 19, 2017	For patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) for whom fludarabine-based treatment is considered inappropriate.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Funded	Dec 28, 2017	Updated criteria: Initial criteria for Treatment naïve patients with high risk CLL/SLL: For patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who present with one of the following cytogenic markers: • chromosome 17p deletion; OR • TP 53 mutation; OR • unmutated immunoglobulin heavy chain variable region (IgHV) Renewal criteria: Patient has experienced no disease progression while on Imbruvica therapy.
NS	Funded	Oct 15, 2018	As a single agent treatment option for patients with previously untreated chronic lymphocytic leukemia (CLL)/ small lymphocytic leukemia (SLL) for whom fludarabine –based treatment is considered inappropriate due to high risk of relapse or refractory disease based on prognostic biomarkers. Treatment should be discontinued upon disease progression or unacceptable toxicity.
NB	Funded	June 11, 2018	For the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) for whom fludarabine-based treatment is considered inappropriate due to high risk of relapse or refractory disease based on prognostic biomarkers. Patients must have a good performance status. Treatment should be discontinued upon disease progression or unacceptable toxicity.
NL	Funded	May 1, 2018	For patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) for whom fludarabine-based treatment is considered inappropriate, such as patients with high risk disease (example: chromosome 17p deletion).
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.